Dual regulation of TxNIP by ChREBP and FoxO1 in liver

HIGHLIGHTS
TxNIP is considered as a potential candidate drug target for type 2 diabetes

We provide better understanding of Txnip regulation and function in liver

Hepatic Txnip is up-regulated by both ChREBP and FoxO1 transcription factors

We suggest a role for TxNIP in the physiological adaptation to nutrient restriction
Dual regulation of TxNIP by ChREBP and FoxO1 in liver

Benedicte Noblet, 1 Fadila Benhamed, 1 InSug O-Sullivan, 2, 3 Wenwei Zhang, 2, 3 Gaëlle Filhoulaud, 1 Alexandra Montagner, 4 Arnaud Polizzi, 4 Solenne Marmier, 1 Anne-Françoise Burnol, 1 Sandra Guilmeau, 1 Tarik Issad, 1 Hervé Guillou, 4 Catherine Bernard, 5 Terry Unterman, 2, 3, * and Catherine Postic 1, 6, *

SUMMARY

TxNIP (Thioredoxin-interacting protein) is considered as a potential drug target for type 2 diabetes. Although TxNIP expression is correlated with hyperglycemia and glucotoxicity in pancreatic β cells, its regulation in liver cells has been less investigated. In the current study, we aim at providing a better understanding of Txnip regulation in hepatocytes in response to physiological stimuli and in the context of hyperglycemia in db/db mice. We focused on regulatory pathways governed by ChREBP (Carbohydrate Responsive Element Binding Protein) and FoxO1 (Forkhead box protein O1), transcription factors that play central roles in mediating the effects of glucose and fasting on gene expression, respectively. Studies using genetically modified mice reveal that hepatic TxNIP is up-regulated by both ChREBP and FoxO1 in liver cells and that its expression strongly correlates with fasting, suggesting a major role for this protein in the physiological adaptation to nutrient restriction.

INTRODUCTION

Thioredoxin-interacting protein (TxNIP/VDUP1/TBP-2) originally discovered as a vitamin D3-inducible gene (Chen and DeLuca, 1994) has gained interest for being involved in glucose homeostasis, carcinogenesis, angiogenesis, or inflammation (Alhawiti et al., 2017; Yoshihara 2020). Structurally designated as part of the α-arrestin family, TxNIP contains two amino-terminal SH3-binding domains, whereas the carboxyl terminus contains two PPxY motifs and three SH3 domains (Patwari et al., 2009). TxNIP binds the anti-oxidant protein, thioredoxin and inhibits its disulfide reductase activity in vitro. In this context, TxNIP has been described as a possible link between cellular redox state and metabolism. Importantly, owing to its diverse array of functions in glucose and lipid metabolism in several cell types, TxNIP has been considered as a novel candidate drug target for type 2 diabetes (Thielen and Shalev, 2018). Interestingly, a study recently identified a novel anti-diabetic small molecule SRI-37330 that inhibits TxNIP expression and signaling in mouse and human islets (Thielen et al., 2020).

TxNIP expression and function have been extensively studied in pancreatic β cells (Shalev, 2014). In this cell type, Txnip is one of the most highly up-regulated genes in response to hyperglycemia (Cha-Molstad et al., 2009). As part of a negative-feedback loop, TxNIP was shown to inhibit glucose uptake and promote caspase-3 cleavage, contributing to glucose-dependent β cell death (Saxena et al., 2010). TxNIP also regulates pro-inflammatory gene expression through inflammasome activation via binding to NLRP3 (NOD-like receptor family pyrin domain containing 3) (Zhou et al., 2010). Altogether, TxNIP has emerged as an important factor in pancreatic β cell biology and tight regulation of Txnip expression levels appears necessary for β cell survival. The mechanisms driving TxNIP expression in pancreatic β cells are complex and involve crosstalk between several transcription factors, including the glucose-sensitive transcription factor Carbohydrate Responsive Element Binding Protein (ChREBP) and the Forkhead box O1 transcription factor (FoxO1). The Txnip promoter contains two carbohydrate response elements (ChoRE) for binding of ChREBP (Minn et al., 2005). FoxO1 was reported to up-regulate Txnip expression in neurons and endothelial cells (Li et al., 2009), whereas it is reported to significantly decrease Txnip expression in pancreatic β cells. Mechanistically, FoxO1 was reported to inhibit Txnip expression by reducing the glucose-induced binding of ChREBP on the Txnip promoter in β cells, suggesting that FoxO1 may antagonize ChREBP for binding to the Txnip promoter in the context of insulin-secreting cells (Kibbe et al., 2013).
Figure 1. TxNIP expression is increased in the liver of db/db mice

Twelve-week-old C57BL/6J (+/+) and db/db male mice were fed ad libitum. Figures are presented as means $\pm$ SEM from 8 to 12 individual mice. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test. *p < 0.5, **p < 0.01, ***p < 0.001, ****p < 0.0005 when compared with (+/+) mice.

(A) Blood glucose (mM) recovered at the time of harvest from tail snip.
(B) Relative Txnip gene expression determined by qPCR.
(C) Western blot analysis of protein extracted from whole-liver lysate. HSP90 was used as loading control. Five representative samples are shown.
(D) pFoxO1/total
(E) Chrebps mRNA, Chrebβ mRNA, Lpk mRNA
(F) ChIP analysis: ChREBP binding

Figure 1. Glycemia (mM)

Figure 1. Txnip mRNA

Figure 1. TXNIP, ChREBPα, ChREBPβ, L-PK, ACC, FoxO1, FoxO1 total, PEPCK, HSP90

Figure 1. pFoxO1/total

Figure 1. ChREBP Lpk

Figure 1. ChREp Txnip

Figure 1. Foxo1 mRNA, Pepck mRNA, G6pase mRNA, Igfbp1 mRNA
The function and the mechanisms regulating 

results in a constitutively active and potent ChREBP isoform lacking the inhibitory LID domain (Her- 

and FoxO1. Studies using genetically modified mouse models of ChREBP and/or FoxO1 expression reveal that, in contrast to pancreatic β cells, hepatic TxNIP is stimu-

In this context, we sought to provide a better understanding of Txnip regulation in hepatocytes in response to physiological stimuli and in the context of diabetes. Owing to their previously reported implication, we focused on pathways governed by ChREBP and FoxO1. Studies using genetically modified mouse models of ChREBP and/or FoxO1 expression reveal that, in contrast to pancreatic β cells, hepatic TxNIP is stimu-

RESULTS

TxNIP expression is increased in liver of db/db mice

We first measured Txnip expression in the liver of fed 

mice (Figure 1). We chose 

mice for their significant hyperglycemia and confirmed that their blood glucose concentrations were elevated compared with controls under our experimental conditions (Figure 1A). As previously reported (Jo et al., 2013), Txnip mRNA levels and TxNIP protein content were significantly increased in the liver of fed 

mice compared with +/+ mice (Figures 1B and 1C). As Txnip was previously reported to be a direct target of ChREBP and/or FoxO1 depending on the cell type studied, we examined the expression and activity of these transcription factors. The ChREBP protein contains a low glucose inhibitory domain (LID) and a glucose responsive activation conserved element (GRACE) located in its N terminus (Li et al., 2006). Activation of the GRACE domain by glucose promotes ChREBP transcriptional activity and binding to the ChoRE element of its target genes. Another isoform of Chrebp, Chrebpβ, originating from an alternative first exon promoter, was identified in the adipose tissue and in liver (Herman et al., 2012). This alternative splicing results in a constitutively active and potent ChREBP isoform lacking the inhibitory LID domain (Her-

An increase in ChoRE binding to the Lpk promoter in the liver of 

mice compared with controls (+/+ ) (Figure 1F). Interest-

Interestingly, FoxO1 protein content was also elevated in the liver of 

mice (Figure 1C). Of note, the level of phospho-FoxO1 was also increased, but in proportion to changes in total FoxO1 level (Figure 1D), indicating that levels of both phospho- (inactive) and nonphospho- (active) FoxO1 are likely increased in 

liver. In contrast, the level of FoxO1 mRNA was not significantly altered in 

mice, suggesting that differences in FoxO1 protein level are due to post-transcriptional mechanisms. A significant increase in the expression of several FoxO1 target genes (Peepck and Gapase) is consistent with increased FoxO1 act-

activity in the liver of 

mice (Figure 1E). Although we did not succeed in performing FoxO1 ChIP assays, our results, nevertheless, indicate that hepatic TxNIP content is increased in the liver of 

mice and parallels with enhanced ChREBP and FoxO1 activity.
Primary hepatocytes derived from adult male mice were incubated under low glucose concentration (5 mM) with specific adenovirus as indicated (from 0.1 to 3.0 PFU/cell) for 24 h.

(A) Relative Chrebp, Foxo1, Acc, Igfbp1, and Tnip gene expression determined by qPCR. Figures are presented as means ± SEM from 6 to 8 independent cultures. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test. **p < 0.01, ***p < 0.001 when compared with GFP conditions.

(B) Schematic representation of the wild and mutated Tnip promoters (1,081 bp; the two ChREBP-binding sites [ChoRE] and the FoxO1-binding site [IRE] are indicated). Primers used for site-directed mutagenesis are indicated in Table S1.

(C) Luciferase activity of the wild-type Tnip promoter in primary hepatocytes in response to either ChREBP<sup>CA</sup> (3 PFU/cell) or FoxO1<sup>CA</sup> (3 PFU/cell). Figures are presented as means ± SEM from 6 to 8 independent cultures. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test. **p < 0.01 when compared with GFP conditions.
(D) Luciferase activity of the wild-type, ChoREa-mutated, or IRE-mutated Txnip promoter in primary hepatocytes in response to either ChREBPCA (3 PFU/cell) or FoxO1CA (3 PFU/cell). Figures are presented as means ± SEM from 5 to 8 independent cultures. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test *p < 0.05, ***p < 0.001 when compared with wild-type promoter activity.

**Figure 2. Continued**

**Direct effects of FoxO1 and ChREBP on Txnip expression in mouse hepatocytes**

To investigate direct effects of ChREBP and/or FoxO1 on Txnip expression in liver cells, overexpression studies of ChREBP or FoxO1 were conducted using adenovirus strategies in vitro. Primary hepatocytes were transfected with increasing concentrations (from 0.1 to 3.0 plaque-forming unit [PFU]/cell) of an adenovirus expressing a constitutively active isoform of ChREBP (ChREBP(GFP)) lacking the low glucose inhibitory domain (LID) (Li et al., 2006), a constitutively active form of FoxO1 (FoxO1(CA)) (Zhang et al., 2006), or green fluorescent protein (GFP) as a control. As shown in Figure 2A ChREBP overexpression (at 3 PFU/cell) increased mRNA levels of Acc, a known ChREBP target gene, but not of Igfbp1, which is regulated by FoxO1. Conversely, FoxO1 overexpression led to a significant increase in the expression of its target gene, Igfbp1, but not of Acc (Figure 2A), demonstrating gene-specific effects of ChREBP and FoxO1 in hepatocytes. Interestingly, both ChREBP and FoxO1 were able to induce Txnip expression. An 8-fold increase in response to ChREBPCA (3 PFU/cell) and a 4-fold stimulation in response to FoxO1CA (3 PFU/cell) were observed (Figure 2A), suggesting that ChREBP and FoxO1 are able to stimulate Txnip expression in hepatocytes in a cell-autonomous fashion.

Next, Txnip promoter activity was measured by performing luciferase reporter gene assays (Figures 2C and 2D), using reporter gene constructs containing the wild-type Txnip promoter sequence or constructs in which ChREBP and/or FoxO1-binding sites are mutated (Figures 2B and Table S1). ChREBP(CA) stimulated by 15-fold wild-type Txnip promoter activity (Figure 2C), whereas a 6-fold effect was observed in response to FoxO1(CA) (Figure 2C). The stimulatory effect of ChREBP(CA) was significantly reduced when one ChREBP-binding site (ChoREa) was mutated but remained unchanged when the FoxO1-binding site (IRE) was mutated (Figure 2D). Similarly, the stimulatory effect of FoxO1(CA) was partially lost when the IRE was mutated on the Txnip promoter but remained unchanged when the ChoREa was mutated (Figure 2D). Together, these results indicate that Txnip expression is under the dual stimulatory control of ChREBP and FoxO1 operating through distinct cis-acting elements within the Txnip promoter in hepatocytes.

**Correlation between TxNIP expression and blood glucose concentrations**

To characterize the physiological regulation of TxNIP in liver, its expression was measured in liver of fasted, freely fed, and refeed mice (Figure 3). Interestingly, whereas TxNIP was described as a highly up-regulated gene in response to glucose (Cha-Molstad et al., 2009), Txnip expression (both mRNA and protein levels) was lower in the liver of refeed than in fasted mice (Figures 3A and 3B). To better understand the regulation of hepatic Txnip expression depending on the nutritional status, we established correlations between the relative amount of Txnip expression as a function of glycemia. We plotted Txnip expression depending on blood glucose concentrations in 32 C57BL/6J mice and calculated the Spearman’s correlation coefficient (R) (Figure 3C). Interestingly, we observed positive correlations between Txnip mRNA levels and low glucose concentrations below 6 mM (Figure 3D, n = 11), and also with elevated glucose concentrations above 13 mM (Figure 3F, n = 5). No positive correlation was found when glucose concentrations were in the normal range, between 6 and 13 mM (Figure 3E, n = 15). Taken together, our results suggest that hepatic Txnip expression correlates with glycemia under both low- and high-glucose conditions.

**Regulation of TxNIP during fasting and refeeding**

To further study the physiological regulation of TxNIP, we next focused on the fasting/refeeding transition, characterized by marked differences in blood glucose concentrations (Figure 4A) and in the ChREBP and FoxO1 activities (Figures 4C and 4D). As expected, the expression of ChREBPα2 and of its target genes Chrebpα and Lpkα were significantly induced in the liver of refeed mice (Figures 4C and 4D). The refeed state was also characterized by an increase in the ratio of phosphorylated FoxO1 to total FoxO1 (Figure 4E) and by decreased PEPCK expression (Figures 4C and 4D), consistent with a reduction in FoxO1 activity. We confirmed that Txnip expression (both mRNA and protein levels) was lower in the liver of refeed than of fasted mice (Figures 4B and 4D). To determine whether ChREBP or FoxO1 was recruited onto the Txnip promoter under these nutritional conditions, ChIP analysis was performed in the liver of fasted and refeed mice (Figure 4F). Under fasted conditions, a significant enrichment of FoxO1 binding on the IRE of the
Pepck promoter was observed. Although it did not reach significance, FoxO1 binding on the IRE of the Txnip promoter was also enriched compared with refed conditions (Figure 4F). As expected, under refed conditions, a marked increase in ChREBP binding was observed on the Lpk ChoRE. Interestingly, a significant enrichment in ChREBP binding was also observed on the ChoRE of the Txnip promoter (Figure 4F).

Altogether, these results support the concept that FoxO1 and ChREBP contribute to the regulation of Txnip expression in the liver under fasting (FoxO1 active) and refed (ChREBP active) conditions.

Glucose-mediated induction of Txnip requires ChREBP
To address the direct contribution of ChREBP to Txnip expression in the refed state, ChREBP was silenced in the liver of mice before fast-refeeding using a validated short hairpin RNA (shRNA) strategy (Dentin et al., 2004). We confirmed that ChREBP protein (Figure 5A) and mRNA (Figure 5B) levels were significantly
Figure 4. Differential regulation of TxNIP during fasting and refeeding. Adult C57BL/6J male mice were studied under fasting (24 h fast) or refeed (a 18-h refeeding period) at ZT12.

Data are expressed as means ± SEM, n = 6 to 8 individual mice/group. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test *p < 0.05, **p < 0.01, ***p < 0.001 when compared with fasted conditions.

(A) Blood glucose (mM) recovered at the time of harvest from tail snip.

(B) Relative Txnip gene expression determined by qPCR.

(C) Relative Chrebpa, Chrebpb, Lpk, and Pepck, gene expression determined by qPCR.

(D) Western blot analysis of protein extracted from whole-liver lysate. HSP90 was used as loading control. Four representative samples are shown.

(E) Quantification of the ratio of phosphorylated FoxO1 corrected to total FoxO1 protein is provided.
Figure 4. Continued
(F) ChIP analysis followed by qPCR of whole mouse liver tissue. Immunoprecipitation experiments conducted with FoxO1 and ChREBP antibodies. The DNA regions of the Pepck, Lpk, and Txnip promoters were amplified using primers indicated in Table S1. Data are expressed as means ± SEM, n = 6 to 8 individual mice/group. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test *p < 0.05, **p < 0.01, ***p < 0.001 when compared with fasted conditions.

Because ChREBP silencing was only partial using the shRNA strategy (Figure 5A), we also examined Txnip regulation in hepatocytes lacking both ChREBP isoforms (Chrebp−/−) (Iroz et al., 2017) (Figure 5C). We observed that Txnip expression was robustly increased in response to 25 mM glucose in wild-type hepatocytes (Chrebp+/+) and was comparable to the increase in Chrebpβ, Lpk, and Acc expression (Figure 5C). The stimulatory effect of glucose was totally prevented for Lpk and Acc in Chrebp−/− hepatocytes, and the induction of Txnip also was significantly reduced, although not completely disrupted, in response to 25 mM in these hepatocytes (Figure 5C). Together, these results confirm that ChREBP-independent mechanisms contribute to the glucose-mediated induction of Txnip in mouse hepatocytes.

Daily rhythms of Txnip correlate with the one of FoxO1
To gain further insight into the physiological regulation of Txnip in liver, we measured its pattern of expression in the liver during daily rhythms under control, fasted, or refeed conditions (Figure 6). Variations in blood glucose concentrations (Figure 6A) and in hepatic RevErbα (a well-known circadian-regulated gene) (Figure 6B) were measured to validate the experimental conditions used. Hepatic mRNA levels of Chrebpα, Chrebpβ, Lpk, Txnip, Pepck, and Foxo1 were measured at ZT0, ZT4, ZT8, ZT12, ZT16, ZT20, and ZT24 by qPCR (Figure 6C). The expression of Chrebpα, Chrebpβ, and Lpk increased in the dark phase in fed mice, when feeding largely occurs, but decreased in the dark under fasting conditions, indicating that diurnal changes in the expression of these genes coincide with changes in food intake. In contrast, the expression of Txnip underwent a different pattern with a major peak of induction at ZT14 in the dark phase under fasting conditions. Interestingly, the profile of Txnip paralleled the one of Foxo1 and of its target gene Pepck (Figure 6C), suggesting that food intake is necessary to prevent the induction and activation of Foxo1, Pepck, and Txnip expression during the transition from light to dark phases. These data support the concept that Txnip expression correlates with the expression of Foxo1 and Pepck in the transition to the fasting state in a physiological context.

FoxO1 stimulates the expression of TnNip in liver
To further characterize the contribution of FoxO1 to the regulation of Txnip in liver, we performed a series of experiments using mice with genetic modifications of the FoxO proteins in liver (Figure 7). First, Txnip expression was measured in the fasting state in the liver of mice with a liver-specific deficiency in the three FoxO proteins (FoxO1, FoxO3, and FoxO4) (LfoxotKO mice) (Zhang et al., 2016). Txnip expression was significantly decreased along with the expression of Igfbp1, a well-known target of FoxO proteins, whereas the expression of Chrebpα, Chrebpβ, and Lpk was only modestly affected (Figure 7A). To address the specific role of FoxO1 on Txnip expression when insulin signaling is decreased, we measured the expression of Txnip in the liver of refeed liver-specific insulin receptor knockout (LIRKO) and IR/FoxO1 double knockout (LIRFoxO1KO) mice (O-Sullivan et al., 2015) (Figure 7B). In the liver of LIRKO mice, where FoxO1 activity is enhanced (O-Sullivan et al., 2015), the expressions of Txnip as well as other FoxO1 targets (Igfbp1 and Pepck) were significantly increased and reversed when FoxO1, the predominant FoxO protein expressed in the liver (Zhang et al., 2016), was knocked out in this model (i.e., LIRFoxO1KO mice) (Figure 7B). These results confirm that endogenous FoxO1 promotes Txnip expression in the liver when insulin signaling is disrupted.

We also analyzed the expression of Txnip in the liver of transgenic mice that selectively express a constitutively active form of FoxO1 in the liver (FoxO1TG) (Zhang et al., 2006). Txnip expression was markedly increased in the liver of FoxO1TG mice and paralleled with changes in the expression of PEPCk at both protein and RNA levels (Figures 7C and 7D). In contrast, ChREBP activity was found to be reduced in the
Figure 5. The glucose-dependent induction of Tnijp requires ChREBP
C57Bl/6J male mice were injected intravenously with a single dose of $5 \times 10^9$ PFU of shCTRL or shChREBP adenovirus at Day 1. Seven days later, mice were challenged to nutritional manipulations as indicated (fasted or refed).
(A) Western blot analysis of protein extracted from whole-liver lysate. HSP90 was used as loading control. Three representative samples are shown. Quantification of the ratio of Tnijp protein content corrected to HSP90 is shown. *$p < 0.05$ when compared with ShControl conditions.
liver of these mice. Indeed, we observed that the expression of Chrebpβ and Lpk was decreased in the liver of FoxO1TGN mice. We hypothesized that this decrease could be due to reduced ChREBP O-GlcNAcylation (ChREBPβ OGlcNAc) (Figure 7C). O-GlcNAcylation is a post-translational modification dependent on glucose metabolism that stimulates ChREBP transcriptional activity in the liver (Guinez et al., 2011). Interestingly, it was previously reported that ChREBPβ OGlcNAcylation is reduced in response to FoxO1 in the liver (Ido-Kitamura et al., 2012), presumably due to the suppression of glucokinase expression and glucose utilization by FoxO1 (Zhang et al., 2006). Together these results indicate that FoxO1 is sufficient to promote Txnip expression in the liver, including under conditions where ChREBP expression and activity are reduced.

Txnip silencing in liver reduces hyperglycemia in db/db mice

We next evaluated the contribution of TxNIP to the hyperglycemic phenotype of db/db mice using a TxNIP shRNA strategy (Figure 8). TxNIP protein content was decreased by 50% in the liver of db/db mice treated with the ShTxnip adenovirus (Figure 8A). This decrease was associated with a significant improvement in the pyruvate tolerance test (PTT), which reflects production of glucose from exogenous pyruvate (Figure 8B). Blood glucose concentrations in db/db ShTxnip mice were significantly reduced compared with db/db ShControl under both fasted and fed states (Figure 8C). No change in body weight was observed upon TxNIP silencing in db/db mice (Figure 8D), indicating that effects of shTxnip on glucose levels and pyruvate tolerance were not due to modification in body weight. Txnip knockdown was associated with a significant decrease in Pепck, G6pase, and Pgc1α expression (Figure 8E).

To determine whether TxNIP silencing also could affect glucose homeostasis in a physiological context, TxNIP was knocked down in the liver of C57Bl/6J mice (Figure S1A). We observed that the PTT was improved in ShTxNIP-treated mice compared with mice injected with a ShControl (Figure S1B). Blood glucose concentrations also were significantly decreased at the time of sacrifice (Figure S1C). qPCR analysis confirmed that Txnip mRNA levels were significantly decreased in the liver of ShTxNIP mice in parallel with reduced expression of gluconeogenic genes, including Pepck and G6pase and the co-activator Pgc1α (Figure S1D). Altogether, these results support a role for TxNIP in regulating hepatic glucose production and gluconeogenic gene expression under hyperglycemic and physiological conditions.

DISCUSSION

In the current study, we sought to provide a better understanding of the mechanisms involved in the regulation of TxNIP in the liver under physiological and hyperglycemic conditions. In recent years, TxNIP has emerged as a key regulator of glucose and lipid metabolism and has been shown to influence metabolic regulation via multiple actions including insulin release from pancreatic β cells, glucose production by the liver, and glucose uptake in peripheral tissues including muscle and adipose tissue (Alhawiti et al., 2017). In addition, genetic and epigenetic variations in TxNIP are associated with chronic metabolic disorders including diabetes and hypertension (van Greevenbroek et al., 2007; Ferreira et al., 2012). Interestingly, anti-diabetic agents like insulin, metformin, glucagon-like peptide-1 (GLP-1) agonists, and resveratrol have been reported to inhibit TxNIP expression, which may contribute to their therapeutic efficacy in the treatment of diabetes (Chai et al., 2012; Bedarida et al., 2016; Nivet-Antoine et al., 2010; Shao et al., 2010). Interestingly, after a screen of more than 300,000 molecules, Thilen and co-workers recently identified a compound that downregulates TxNIP in mouse and human pancreatic islets. When given orally to mice, this small molecule (SRI-37330) lowered serum levels of glucagon, prevented fatty liver, and inhibited glucose production by the liver (Thilen et al., 2020). In this context, TxNIP continues to generate significant interest as a potential therapeutic target for the management of diabetes and other metabolic disorders (Yoshihara, 2020). We report in the present study that TxNIP is dually regulated in the liver by the transcription factors ChREBP and FoxO1 under specific nutritional conditions.
TxNIP can be induced by glucose in a ChREBP-dependent fashion in a variety of cell types and the TxNIP promoter contains two ChREBP response elements (Cha-Molstad et al., 2009). Txnip is one of the most highly up-regulated genes in response to glucose in pancreatic β cells (Cha-Molstad et al., 2009) where its induction by glucose was previously reported to be ChREBP dependent (Minn et al., 2005). Our study shows that Txnip expression also is significantly up-regulated by high glucose concentrations in primary hepatocytes and that the glucose-sensitive transcription factor ChREBP contributes to glucose-mediated induction of Txnip in hepatocytes. Although the results demonstrate that ChREBP does contribute to the induction of TxNIP in refed conditions, our data also suggest that other molecular mechanisms may be involved. Indeed, a significant (although reduced) glucose effect was maintained on Txnip in Chrebp−/−.
Figure 7. FoxO1 stimulates the expression of TXNIP in liver

(A and B) (A) Wild-type (WT) and LFoxO1TKO mice were fasted for 24 h qPCR analysis of Foxo1, Foxo3, Igfbp1, Txnip, Chrebpα, Chrebpβ, and Lpk. Data are expressed as means ± SEM, n = 6 to 8 individual mice/group. Significance is based on two-way ANOVA followed by Bonferroni post hoc test, **p < 0.01, ***p < 0.001 when compared with WT mice. (B) Wild-type (WT), LIR KO, and LIRFoxO1 KO mice were studied at the fed state. qPCR analysis of InsR, Txnip, Igfbp1, Pecpk, and Foxo1. Data are expressed as means ± SEM, n = 6 to 8 individual mice/group. Significance is based on two-way ANOVA followed by Bonferroni post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001 when compared with LIRKO mice.

(C and D) Control (CTRL) and transgenic mice overexpressing a constitutive active form of FoxO1 (FoxO1TGN) were studied at the fed state. (C) Western blot analysis of protein extracted from whole liver lysate. GAPDH was used as loading.
followed by Bonferroni post hoc test. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test.

In fact, the contribution of MondoA to liver metabolism was previously evidenced by its direct control of the Chrebp and proliferative cells (Wilde and Ayer, 2015), a role for MondoA in hepatocytes should not be excluded. MondoA to the Chrebp and Txnip for Lpk.

Surprisingly, unlike other ChREBP targets, our study reveals that liver Tnxip expression is higher under fasting than under refed conditions. Interestingly, correlation studies established that Tnxip mRNA levels correlate with both low glucose concentrations (below 6 mM) and elevated glucose concentrations (above 13 mM). In the liver of hyperglycemic db/db mice, we confirmed that Tnxip expression is elevated and that ChREBP binding is enriched on the ChoRE of the Tnxip promoter. In this mouse model, we cannot exclude that elevated Tnxip expression also could result from enhanced glucocorticoid signaling or other factors. Indeed, several studies have suggested that chronic corticosterone treatment may upregulate Tnxip by targeting the glucocorticoid receptor (Bharti et al., 2018; Reich et al., 2012). Glucocorticoids have been shown to regulate Tnxip in neuronal cells (Bharti et al., 2018) and often function cooperatively to regulate the expression of FoxO1 target genes in the liver, including Pepck, G6pase, and IGFBP-1 (Goswami et al., 1994). Interestingly, our study suggests that FoxO1 activity may be enhanced in the liver of db/db mice, where FoxO1 is known to play a significant role in promoting hyperglycemia (Zhang et al., 2012). Although we were not able to address the direct contribution of FoxO1 to the expression of Tnxip in the liver of db/db mice due to unresolved technical problems, we were able to demonstrate that FoxO1 plays a key role in promoting Tnxip expression in the liver, based on complementary approaches in vitro and in vivo.

To date, the role of FoxO1 on Tnxip expression has been rather complex. FoxO1 was reported to stimulate Tnxip expression in neurons (AI-Mubarak et al., 2009) and glucose-treated endothelial cells (Li et al., 2009), and to down-regulate its expression in liver tumor cells (de Canda et al., 2008). A study also reported that the expression of FoxO1 and Tnxip is inversely correlated in alcohol-induced hepatitis. However, this study did not examine the direct effect of FoxO1 on Tnxip expression in liver cells in this pathophysiological context (Heo et al., 2019). Here, we report that FoxO proteins contribute to the regulation of Tnxip in the liver under a variety of physiological conditions. Using liver-specific knockout mice, we demonstrate that Tnxip expression is strongly induced during the fasting state in a FoxO-dependent manner, and that FoxO1, the major FoxO protein expressed in the liver (Zhang et al., 2016), plays a crucial role in promoting Tnxip expression when insulin signaling is disrupted in the liver of LIR-KO mice. Studies in transgenic mice expressing a constitutively active form of FoxO1 in the liver also demonstrated that FoxO1 promotes the expression of Tnxip in the liver, and studies with adenoviral vectors demonstrated that FoxO1 stimulates hepatic Tnxip expression in primary hepatocytes in a cell-autonomous fashion. Reporter gene studies and ChIP analysis showed that this effect of FoxO1 is mediated through the cis-acting FoxO1 target site located in the Tnxip promoter, supporting the concept that Tnxip is a direct downstream target of FoxO1 in the liver (Zhang et al., 2012). Together, these data provide strong support for the concept that FoxO1 promotes Tnxip expression in the liver under conditions where insulin levels are low (fasting) or insulin signaling is impaired.

Crosstalk between FoxO1 and ChREBP was previously reported in pancreatic β cells (Kibbe et al., 2013). In these cells, FoxO1 was reported to inhibit the ability of ChREBP to stimulate Tnxip expression, and it was suggested that FoxO1 might exert this effect by binding to a FoxO target site overlapping a nearby ChoRE in the Tnxip promoter, thereby displacing ChREBP from its ChoRE (Kibbe et al., 2013). In addition, FoxO1 has been reported to suppress the expression of glucokinase in pancreatic β cells (Buteau et al., 2007) similar to the liver, and might therefore limit ChREBP’s ability to activate Tnxip promoter by an indirect mechanism. In the present study, we found that FoxO1 and ChREBP are able to both stimulate the expression of Tnxip in hepatocytes. Although...
Figure 8. *Txnip* silencing in liver reduces hyperglycemia in *db/db* mice  
Adult C57BL/6J (+/+) and *db/db* male mice were injected intravenously with a single dose of 5 × 10⁹ PFU of ShControl or ShTxnip adenovirus (GeneCust) at Day1. Seven days later, mice were challenged to a pyruvate tolerance test (PTT) or to nutritional manipulations as indicated (a 24-h fast [Fasted] or analyzed at the fed state [Fed]). Data are expressed as means ± SEM, n = 6 to 8 individual mice/group. Significance is based on two-way ANOVA followed by Bonferroni post hoc test. (A) Western blot analysis of protein extracted from whole-liver lysate. HSP90 was used as loading control. Four
In our study, we have provided a molecular basis to explain the dual regulation of TxNIP in response to fasting and refeeding in liver, via the transcription factors FoxO1 and ChREBP, respectively. However, we have not
clearly determined which of these two factors contributes to enhanced TxNIP expression in the liver of hyperglycemic db/db mice. In addition, although we report that TxNIP silencing reduces blood glucose concentrations and improves PTTs in C57Bl/6J and db/db mice, the mechanism(s) involved was not elucidated.

**Resource availability**

**Lead contact**
Further information, requests, and inquiries should be directed to and will be fulfilled by the lead contact, Catherine Postic (catherine.postic@inserm.fr).

**Materials availability**
All tables and figures are included in the text and supplemental information.

**Data and code availability**
The published article includes all data generated or analyzed during this study.

**METHODS**
All methods can be found in the accompanying Transparent methods supplemental file.

**SUPPLEMENTAL INFORMATION**
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.102218.

**ACKNOWLEDGMENTS**
The authors thank E. Anthony (U1016-Institut Cochin), C. Naylies (GeT-TRiX, INRA ToxAlim), and G. Michel for providing excellent technical assistance. The authors would like to thank R. Dentin and F. Levavasseur (U1016-Institut Cochin) for the use of the ChREBP knockout mouse model. We also thank the animal facility staff (EZOP, INRA ToxAlim) for their excellent work. Postic’s lab (U1016-Institut Cochin) is supported by grants from Servier Laboratories, FRM (Foundation for the Medical Research, DEQ20150331744), EFSD-Novonordisk (European Foundation for the Study of Diabetes), and National Agency for Research (ANR (ANR-15-CE14-0026-Hepatokind). Unterman’s lab is supported by VA Merit Review Grant (IO1BX001968).

**AUTHOR CONTRIBUTIONS**
B.N., F.B., I.O.-S., W.Z., G.F., A.M., A.P., and S.M. designed experiments, performed experiments, and analyzed the data. F.B., A.-F.B., S.G., T.I., H.G., and C.B. contributed to the critical review of the manuscript. C.P. and T.U. analyzed the data and wrote the manuscript.

**DECLARATION OF INTERESTS**
The authors declare no conflict of interest.

Received: March 2, 2020
Revised: November 17, 2020
Accepted: February 18, 2021
Published: March 19, 2021

**REFERENCES**
Abdul-Wahed, A., Guilmeau, S., and Postic, C. (2017). Sweet sixteenth for ChREBP: established roles and future goals. Cell Metab. 26, 324–341.

Ahn, B., Soundarapandian, M.M., Sessions, H., Peddibhotla, S., Roth, G.P., Li, J.L., Sugarman, E., Koo, A., Malany, S., Wang, M., et al. (2016). MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J. Clin. Invest. 126, 3567–3579.

Alhawiti, N.M., Al Mahri, S., Aziz, M.A., Malik, S.S., and Mohammad, S. (2017). TXNIP in metabolic regulation: physiological role and therapeutic outlook. Curr. Drug Targets 18, 1095–1103.

Ali-Mubarak, B., Soriano, F.X., and Hardingham, G.E. (2009). Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene. Channels (Austin) 3, 233–238.

Bedarida, T., Baron, S., Vibert, F., Ayer, A., Henriot, D., Thioulore, E., Marchiol, C., Beaudeux, J.L., Cottart, C.H., and Nivet-Antoine, V. (2016). Resveratrol decreases TXNIP mRNA and protein nuclear expressions with an arterial function improvement in old mice. J. Gerontol. A. Biol. Sci. Med. Sci. 71, 720–729.

Bharti, V., Tan, H., Chow, D., Wang, Y., Nagakannan, P., Eftekharzadeh, E., and Wang, J.F. (2018). Glucocorticoid upregulates thioredoxin-interacting protein in cultured neuronal cells. Neuroscience 384, 375–383.

Brocker, C.N., Kim, D., Melia, T., Karri, K., Velenosi, T.J., Takahashi, S., Aizura, D., Bono, J.A., Levi, M., Waxman, D.J., et al. (2020). Long
non-coding RNA Gm15441 attenuates hepatic inflammation and activation in response to PPARalpha agonism and fasting. Nat. Commun. 71, 5847–5863.

Buteau, J., Shilen, A., Foisy, S., and Accili, D. (2007). Metabolic diapause in pancreatic beta-cells expressing a gain-of-function mutant of the forkhead protein FoxO1. J. Biol. Chem. 282, 287–293.

de Candia, P., Blehman, R., Chabot, A.E., Oshlack, A., and Gilad, Y. (2008). A combination of genomic approaches reveals the role of FOXO1a in regulating an oxidative stress response pathway. PLoS One 3, e1670.

Cha-Molstad, H., Saxena, G., Chen, J., and Shalev, A. (2009). Glucose-stimulated expression of Tnip is mediated by carbohydrate response element-binding protein, p300, and histone H4 acetylation in pancreatic beta cells. J. Biol. Chem. 284, 16989–16995.

Chai, T.F., Hong, S.Y., He, H., Zheng, L., Hagen, T., and Wang, Y. (2012). A potential mechanism of metformin-mediated regulation of glucose homeostasis: inhibition of Thioredoxin-interacting protein (Tnip) gene expression. Cell Signal. 24, 1700–1705.

Chen, K.S., and DeLuca, H.F. (1994). Isolation and characterization of a novel cDNA from HL-60 cells expressing a gain-of-function mutant of the forkhead protein FoxO1. J. Biol. Chem. 269, 23194–23202.

Dentin, R., P´egorier, J.P., Benhamed, F., Foufelle, F., Ferre´, P., Fauveau, V., Magnuson, M.A., Girard, O.S., and David, F. (2009). Hepatic FoxO1 integrates glucose utilization and lipid synthesis through regulation of ChREBP O-glycosylation. PLoS One 4, e74231.

Forbes, K.J., and Sherratt, D.A. (2006). Glucose-dependent induction of the beta-cell. Mol. Endocrinol. 20, 102218, March 19, 2021.

Goswami, R., Lacson, R., Yang, E., Sam, R., and Unterman, T. (1994). Functional analysis of glucocorticoid and insulin response sequences in the rat insulin-like growth factor-binding protein-1 promoter. Endocrinology 134, 736–743.

van Greevenbroek, M.M., Vermeulen, V.M., Feskens, E.J., Elov, C.T., Kruijshaap, M., Hoebee, B., van der Kallen, C.J., and de Bruin, T.W. (2007). Genetic variation in thioredoxin-interacting protein (TXNIP) is associated with hypertriglyceridaemia and blood pressure in diabetes mellitus. Diabet Med. 24, 498–504.

Guinez, C., Filhaudou, G., Rayan-Benhamed, F, Marmier, S., Dubuquoy, C., Denton, R., Molides, M., Burrol, A.F., Yang, X., Lefebvre, T., et al. (2011). O-GlcNAcylation increases ChREBP promoter transactivation and transcriptional activity in the liver. Diabetes 60, 1399–1413.

Hand, L.E., Saer, B.R., Hui, S.T., Jinmann, H.A., Stenlechner, S., Loudon, A.S., and Bechtold, D.A. (2013). Induction of the metabolic regulator Tnip in fasting-induced and natural torpor. Endocrinology 154, 2081–2091.

Heo, M.J., Kim, T.H., Yoo, J.S., Blaya, D., Sancho-Bru, P., and Kim, S.G. (2019). Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TNXIP overexpression. Gut 68, 706–710.

Herman, M.A., Peroni, O.D., Villoria, J., Schön, M.R., Aburand, N.A., Blüher, M., Klein, S., and Kahn, B.B. (2012). A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 484, 333–338.

Hui, T.Y., Sheth, S.S., Diffley, J.M., Potter, D.W., Lussis, A.J., Attie, A.D., and Davis, R.A. (2004). Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals. J. Biol. Chem. 279, 24387–24393.

Icko-Kitamura, Y., Sasaki, T., Kobayashi, M., Kim, H.J., Lee, Y.S., Kikuchi, O., Yokota-Hashimoto, H., Izuka, K., Accili, D., and Kitamura, T. (2012). Hepatic FoxO1 integrates glucose utilization and lipid synthesis through regulation of ChREBP O-glycosylation. PLoS One 7, e47231.

Iroz, A., Montagner, A., Benhamed, F., Levavasseur, F., Polizzi, A., Anthony, É., Régnier, M., Fouché, C., Lukowicz, C., Cazauç, M., et al. (2017). A specific ChREBP and PPARα cross-talk is required for the glucose-mediated PGC1α response. Cell Rep. 21, 403–416.

Jo, S.H., Kim, M.Y., Park, J.M., Kim, T.H., and Ahn, Y.H. (2013). Tnip contributes to impaired glucose tolerance by upregulating the expression of genes involved in hepatic glucose homeostasis in mice. Diabetologia 56, 2723–2732.

Kibbe, C., Chen, J., Xu, G., Jing, G., and Shalev, A. (2013). FOXO1 competes with carbohydrate response element-binding protein (ChREBP) and inhibits thioredoxin-interacting protein (TXNIP) transcription in pancreatic beta cells. J. Biol. Chem. 288, 23194–23202.

Li, M.V., Chang, B., Imamura, M., Poungvarin, N., and Chan, L. (2006). Glucose-dependent transcriptional regulation by an evolutionarily conserved glucose-sensing module. Diabetes 55, 1179–1189.

Li, X., Rong, Y., Zhang, M., Wang, X.L., LeMaire, S.A., Costilla, J.S., Zhang, Y., and Shen, Y.H. (2009). Up-regulation of thioredoxin interacting protein (Tnip) by p38 MAPK and FOXO1 contributes to diabetes mellitus. Diabetes 58, 5847–5863.
Zhang, W., Patil, S., Chauhan, B., Guo, S., Powell, D.R., Le, J., Klotsas, A., Matika, R., Xiao, X., Franks, R., et al. (2006). FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem. 281, 10105–10117.

Zhang, K., Li, L., Qi, Y., Zhu, X., Gan, B., DePinho, R.A., Averitt, T., and Guo, S. (2012). Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice. Endocrinology 153, 631–646.

Zhang, W., Bu, S.Y., Mashek, M.T., O’Sullivan, I., Sibai, Z., Khan, S.A., Ikayeva, O., Newgard, C.B., Mashek, D.G., and Unterman, T.G. (2016). Integrated regulation of hepatic lipid and glucose metabolism by adipose triacylglycerol lipase and FoxO proteins. Cell Rep 15, 349–359.

Zhou, R., Tardivel, A., Thorens, B., Choi, I., and Tschopp, J. (2010). Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136–140.
Supplemental information

Dual regulation of TxNIP
by ChREBP and FoxO1 in liver

Benedicte Noblet, Fadila Benhamed, InSug O-Sullivan, Wenwei Zhang, Gaëlle Filhoulaud, Alexandra Montagner, Arnaud Polizzi, Solenne Marmier, Anne-Françoise Burnol, Sandra Guilmeau, Tarik Issad, Hervé Guillou, Catherine Bernard, Terry Unterman, and Catherine Postic
Figure S1. *Txnip* silencing in liver reduces blood glucose concentrations in C57BL/6J mice. Related to Figure 8.

Adult C57BL/6J male mice were injected intravenously with a single dose of $5 \times 10^9$ pfu of ShControl or ShTxnip adenovirus (GeneCust) at Day1. Seven days later, mice were challenged to a pyruvate tolerance test (PTT). Data are expressed as means ± SEM, n=6 to 8 individual mice/group. Significance is based on two-way ANOVA followed by Bonferroni post hoc test, *p<0.05, **p<0.01, when compared to ShControl (A) Pyruvate tolerance test (PTT) (C). Blood glucose concentrations at sacrifice. (D). qPCR analysis of *Txnip, G6Pase, Pepck, Foxo and PGC1α*. 
Table S1. Sequences of PCR primers used for mutagenesis. Related to Figure 2.

| Forward Primer | Reverse Primer |
|----------------|----------------|
| **ChoRE<sub>2</sub> WT** | CTG TGC **ACG ACG** GCT GCA CGA GCC TCC | GGA GGC TCG TGC AGC CCT CGT GCA CAG |
| **ChoRE<sub>2</sub> mutated** | CTG TGC **ACC ATG** GCT **GGA** CGA GCC TCC | GGA GGC TCG TCC AGC CAT GGT GCA CAG |
| **IRE WT** | AGG CCT **GCT AAA CAA GGG** CCA AGT A | TAC TTG GCC CTG GTT TAC CAG GCC T |
| **IRE partial mutant 1** | AGG CCT **AGT AAC CAA GGG** CCA AGT A | TAC TTG GCC CTG GTT TAC TAG GCC T |
| **IRE partial mutant 2** | AGG TCT **AGC AAC CAA GGG** CCA AGT A | TAC TTG GCC CTG GTG TGC TAG ACC T |
| **IRE mutated** | AGG TCT **AGC AAC CAA TGG CCA AGT A** | TAC TTG GCC ATT GTG TGC TAG ACC T |

The consensus sequences for recognition and binding of the transcription factors ChREBP and FoxO1 are underlined. The sequences of the endogenous promoter (murine-WT) are indicated for comparison. Mutations are indicated in red. The 'IRE partial mutant 1' mutant serves as a template for obtaining the 'IRE mutated' (last lane). Abbreviations: ChoREa, Carbohydrate Response Element proximal to the *Txnip* promoter; IRE, Insulin Response Element; WT, unmutated wild type promoter.
Table S2. Sequences of the primers used for qPCR and ChIP-qPCR. Related to Figures 1, 3, 4, 5, 6, 7, 8 and S1.

|       | Forward | Reverse |
|-------|---------|---------|
| Acc   | GAG GTG GCT AAG AGG AGG CTC T | CAG CAC CGA GAC TGA ACT GTA AGG |
| Chrebpb total | ATG ACC CCT CAC TCA GGG AAT A | GAT CCA AGG GTC CAG AGC AG |
| Chrebpb α | CGA CAC TCA CCC ACC TCT TC | TTG TTC AGC CGG ATC TTG TC |
| Chrebpb β | TGT GCA GAT CCG GTG GAG | CTT GTC CCG GCA TAG GAA C |
| Foxo1 | TGT TAC TTA GCT CTC TCC CCG CG | AGA CGA GCA GTG GCT CAA T |
| Foxo1 (TGN) | GGA TGG TGA AGA GCG TGC CC | CGC TCT TGC CTC CCT CCG GA |
| Foxo3 | CTTCAGGCTCCTCAGTGA | ATGAGTTCACTACGGATGAT |
| G6Pase | TTA CCA GGC TCC TGT CGG | GAC ACA ACT GAA GCC GGT TAG |
| Lpk | CTT GCT CTA CCG TGA GCC TC | ACC ACA ATC ACC AGA TCA CC |
| Txnip | GAC TAG AGA GCC CCA CCA CC | GGA CTC ACG GAT CCA CCT CA |
| Igfbp1 | CCT GCC AAC GAG AAC TCT AT | AGG GAT TTT CTT TCC ACT CC |
| Pepck | TGG CTA CGT CCC TAA GGA A | GGT CCT CCA GAT ACT TGT CGA |
| Cyclophilin | ATG GCA GTG GTG GCA AGT CC | TTG CCA TTC C TG GAC CCA AA |
| Tbp | CCC CAC AAC TCT TCC ATT CT | GCA GGA GTG ATA GGG GTC AT |
| Chrebpb Lpk | GTC CCA CAC TTT GGA AGC AT | CCC GAA CAC TGA TTG TAC CC |
| Chrebpb Tn xip | AAG GGC CAA GTA GCC AAT GGG | GTG CTG GCC TGG AGG |
| IRE Pepck | TAC AGA CAT TAT CTA GAA GTC TCA | CAA GGG CAG GCC TAG CCG AGA |
| IRE Tn xip | AAC AAC AAC CAT TTT CCC CGC TAG | ATA GCC GCC TGG CTT GGC GCT |
Table S3. Antibodies and dilutions used for Western Blot analysis. Related to Figures 1, 3, 4, 5, 7, 8 and S1.

| Protein | Size (kDa) | Dilution (solution) | Secondary | Reference |
|---------|------------|---------------------|-----------|-----------|
| ACC     | 265        | 1/5000 (BSA 5%)     | Rabbit    | Cell Signaling (#3662) |
| ChREBP  | 93         | 1/3000 (BSA 5%)     | Rabbit    | Nouvs (Nb400-135) |
| FoxO1   | 70         | 1/1000 (BSA 5%)     | Rabbit    | Cell Signaling (#2880) |
| GAPDH   | 36         | 1/2000 (lait 5%)    | Rabbit    | Santa Cruz (sc-25778) |
| HSP90   | 85         | 1/1000 (lait 5%)    | Rabbit    | Cell Signaling (#4874) |
| L-PK    | 62         | 1/300 (BSA 2%)      | Rabbit    | Dr A. Kahn (Cochin) |
| PEPCK   | 69         | 1/2000 (lait 5%)    | Rabbit    | Santa Cruz (sc-32879) |
| eFoxO1  | 70         | 1/800 (BSA 5%)      | Rabbit    | Cell Signaling (#9461) |
| TnNIP   | 44         | 1/2000 (lait 5%)    | Mice      | MBL (K0205-3) |
Transparent Methods

Animals
Ten to twelve week-old adult male C57BL/6J, db/db, Chrebp<sup>+/+</sup> and Chrebp<sup>−/−</sup> (Iroz et al., 2017), transgenic mice overexpressing a constitutively active form of FoxO1 in liver (FoxO1<sub>GN</sub>) (Zhang et al., 2006), liver specific triple FoxO1, 3, 4 knockout (LFOXOTK0) (Zhang et al., 2016), liver specific insulin receptor knockout (LIR<sup>KO</sup>) and liver specific insulin receptor and FoxO1 double knockout (LIRFoxO1<sup>KO</sup>) (O-Sullivan et al., 2015) mice were used for in vitro and in vivo experiments as indicated. Procedures were carried out according to the French guidelines for the care and use of experimental animals (Animal authorization agreement n° CEEA34.AFB/CP.082.12, Paris Descartes Ethical Committee). Mice were maintained in a 12-hour light/dark cycle with water and standard diet (65% carbohydrate, 11% fat, and 24% protein) unless specified.

Nutritional and circadian challenges
Mice were studied in the fasted, fed or refed state. ZT stands for Zeitgeber time: ZT0 is defined as the time when the lights are turned on and ZT12 as the time when lights are turned off (7 pm). The fed group was fed ad libitum. The fasted group was fasted from ZT0 until ZT12. The refed group was fasted from ZT0 to ZT12 (included) and refed from ZT12 to ZT24. For circadian rhythms experiments, mice were killed by cervical dislocation at several time points in a pair-wise manner: ZT0, ZT4, ZT8, ZT12, ZT14, ZT16, ZT20, ZT24 as indicated. Liver was removed, snap-frozen in liquid nitrogen and stored at −80 °C until use.

Primary cultures of mouse hepatocytes
Mouse hepatocytes were isolated as described (Dentin et al., 2004). Briefly, hepatocytes were isolated from the livers of fed male mice by a modification of the collagenase method (Berry and Friend, 1969). Briefly, livers from mice were perfused with Hank's balanced salt solution (HBSS, KCl, 5.4 mm; KH<sub>2</sub>PO<sub>4</sub>, 0.45 mm; NaCl, 138 mm; NaHCO<sub>3</sub>, 4.2 mm; Na<sub>2</sub>HPO<sub>4</sub>, 0.34 mm; glucose, 5.5 mm; HEPES, 1 m; EGTA, 50 mm; CaCl<sub>2</sub>, 50 mm; pH 7.4). Livers were washed at a rate of 5 ml/min using the portal vein before collagenase (0.025%) was added. Cell viability was assessed by the trypan blue exclusion test and was always higher than 60%. Hepatocytes were seeded (in 60-mm Petri dishes at a density of 2 × 10<sup>6</sup> cells for RNA extraction or 6-well plates at a density of 4 × 10<sup>5</sup> cells per well for luciferase assays) in medium M199 with Earle salts (Invitrogen), supplemented with 10 µg/ml of streptomycin, 100 units/ml of
penicillin, 2.4 mm of glutamine, 0.1% (w/v) bovine serum albumin, 2% (v/v) Ultrocer G (Invitrogen), 100 nm dexamethasone (Solu decadron, Merck Sharp), and 100 nm insulin (Actrapid, Novo-Nordisk). After cell attachment (6 h), the medium was replaced by fresh M199 medium for 24 h. For adenoviral infections, hepatocytes from C57BL/6J male mice were incubated under low glucose concentration (5 mM) with specific adenovirus (from 0.1 to 3 pfu/cell) for 24 h. For glucose stimulation experiments, hepatocytes from Chrebp<sup>+/+</sup> and Chrebp<sup>−/−</sup> mice (Iroz et al., 2017) were incubated in the presence of low (5mM) or high glucose concentrations (25 mM) for 24 hours.

**Adenoviral injection in vivo**

To silence TxNIP expression, adult C57BL/6J (+/+) and <i>db/db</i> male mice were injected intravenously with a single dose of 5.0x10<sup>9</sup> pfu of ShControl or ShTxnip adenovirus (GeneCust) at Day1. At Day 4, fasting blood glucose was measured. At Day 7, mice were challenged with a pyruvate tolerance test (PTT). At Day 8, fed blood glucose concentrations were measured. Mice were sacrificed under fasting conditions. To silence ChREBP, adult C57BL/6J male mice were injected with a single dose of 5.0x10<sup>9</sup> pfu of ShControl or ShChREBP adenovirus (GeneCust) at Day1. Seven days later, mice were challenged to nutritional manipulations as indicated (Fasted or Refed) before sacrifice.

**Pyruvate tolerance test**

Intraperitoneal pyruvate tolerance test (PTT, 2g/kg body weight) was performed in overnight fasted awake adult C57BL/6J (+/+) and <i>db/db</i> mice 7 days post adenovirus injection.

**Mutagenesis and Luciferase assays**

A TxNIP promoter-luciferase reporter plasmid (pGL3B-1081) was obtained from Addgene (cat #18758). Hepatocytes from C57BL/6J male mice were plated in 6-well plates (4 × 10<sup>5</sup> cells per well) and transfected with TxNIP luciferase reporter constructs (0.2 µg DNA per well) including either Wild type or mutated on the ChoRE (ChoREa mutated) or on the IRE (IRE mutated) (Yu et al., 2009) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Mutants were generated using oligonucleotides described in Table S1. The luciferase assay was conducted using the dual luciferase substrate system (E1501; Promega, Madison, WI), and the result was normalized with the internal control Beta galactosidase. Each experiment was performed in triplicate and repeated 5 to 8 times as indicated.
**ChIP analysis**

*In vivo* ChiP assays from mouse livers were performed as described (Marmier et al., 2015). Briefly, genomic DNA regions of interest were isolated using antibodies against ChREBP (Novus) or Fox01 (Cell Signaling) or non-immune IgG as a control (Cell Signaling). QPCR reactions were carried out in triplicate using SYBR Green Supermix (Bio-Rad) on a CFX Connect™ Real Time PCR system. Positive and negative control sites were tested for each factor as well as the sites of interest. The resulting signals were normalized for primer efficiency by carrying out qPCR for each primer pair using input DNA (pooled unprecipitated genomic DNA from each sample). DNA fragments were quantified by qPCR, using primers described in Table S2. Results are expressed as fold enrichment.

**Gene expression analysis**

Total cellular RNA was extracted using the SV total RNA isolation system (Promega). For qPCR analysis, total RNA samples (2 µg) were reversed transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Primers for SYBR Green assays are presented in Table S2. Amplifications were performed on an ABI Prism 7300 Real Time PCR System (Applied Biosystems). qPCR data were normalized by TATA-box binding protein (TBP) mRNA levels and analyzed with LinRegPCR.22.

**Western blotting analysis**

Proteins from liver lysates were subjected to 10% SDS-PAGE gel electrophoresis and transferred to nitrocellulose membranes. Antibodies and dilutions used are indicated in Table S3.

**Wheat germ agglutinin purification**

For ChREBP immunoprecipitation, cells were lysed on IPH buffer (20 mmol/L Tris/HCl, 150 mmol/L NaCl, 0.5% NP-40 [v/v], and protease inhibitors) as described (Guinez et al., 2011). Briefly, proteins were incubated with 2 µg of anti-ChREBP antibody (Novus) and placed at 4°C overnight. Bound proteins were recovered after addition of 30 µl of Sepharose-labeled protein G (Sigma) for 1 h at 4°C. Beads were gently centrifuged for 1 min and washed four times for 5 min each. For wheat germ agglutinin ([WGA] a GlcNAc-binding lectin) precipitation, 1 mg of proteins was incubated with 30 µl of WGA agarose beads (Sigma). Then, proteins were eluted from the beads in a Laemmli buffer and separated by SDS-PAGE.
**Biochemical analysis**

Blood glucose was measured in total blood using an Accu-Check glucometer (Roche).

**Statistical Analysis**

Data representing at least three independent experiments are reported as means ± S.E.M, and were analyzed using Prism 5.0, GraphPad) software. A student’s T-test was used when comparing two groups (followed by Mann-Whitney post hoc test) or two-way ANOVA when comparing three or more groups followed by a Bonferroni post hoc test. Statistical significance was defined as $p<0.05$. 
Supplemental References

Berry, M.N., and Friend, D.S. (1969). High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J. Cell Biol. 43, 506-520.

Dentin, R., Pégorier, J.P., Benhamed, F., Foufelle, F., Ferré, P., Fauveau, V., Magnuson, M.A., Girard, J., and Postic, C (2004). Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem. 279, 20314–20326.

Guinez, C., Filhoulaud, G., Rayah-Benhamed, F., Marmier, S., Dubuquoy, C., Dentin, R., Moldes, M., Burnol, A.F., Yang, X., Lefebvre, T., et al. (2011) O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes. 60, 1399–1413.

Iroz, A., Montagner, A., Benhamed, F., Levavasseur, F., Polizzi, A., Anthony, E., Régnier, M., Fouché, E., Lukowicz, C., Cauzac, M., et al. (2017). A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response. Cell Rep. 21, 403–416.

Marmier, S., Dentin, R., Daujat-Chavanieu, M., Guillou, H., Bertrand-Michel, J., Gerbal-Chaloin, S., Girard, J., Lotersztajn, S., and Postic, C. (2015). Novel role for carbohydrate responsive element binding protein in the control of ethanol metabolism and susceptibility to binge drinking. Hepatology 62, 1086-100.

O-Sullivan, I., Zhang, W., Wasserman, D.H., Liew, C.W., Liu, J., Paik, J., DePinho, R.A., Stolz, D.B., Kahn, C.R., Schwartz, M.W., and Unterman, T.G. (2015). FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization Nat Commun. 6, 7861.

Yu, F.X., and Luo, Y. Tandem ChoRE and CCAAT motifs and associated factors regulate Txnip expression in response to glucose or adenosine-containing molecules. (2009). PLoS One 4, e8397.

Zhang, W., Patil, S., Chauhan, B., Guo, S., Powell, D.R., Le, J., Klotsas, A., Matika, R., Xiao, X., Franks, R., et al. (2006). FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem. 281, 10105–10117.

Zhang, W., Bu, S.Y., Mashek, M.T., O-Sullivan, I., Sibai, Z., Khan, S.A., Ilkayeva, O., Newgard, C.B., Mashek, D.G., and Unterman TG. Integrated Regulation of Hepatic Lipid and Glucose Metabolism by Adipose Triacylglycerol Lipase and FoxO Proteins (2016). Cell Rep. 15, 349-359.